Skip to Content


Active Substance: vorapaxar sulfate
Common Name: vorapaxar
ATC Code: B01
Marketing Authorisation Holder: Merck Sharp & Dohme Limited
Active Substance: vorapaxar sulfate
Status: Withdrawn
Authorisation Date: 2015-01-19
Therapeutic Area: Myocardial Infarction
Pharmacotherapeutic Group: Antithrombotic agents

Therapeutic Indication

Zontivityis indicated for the reduction of atherothrombotic events in adult patients with

- a history of myocardial infarction (MI), ,co-administered with acetylsalicylic acid (ASA) and, where appropriate, clopidogrel; or

- symptomatic peripheral arterial disease

(PAD), co-administered with acetylsalicylic acid (ASA) or, where appropriate, clopidogrel.

The marketing authorisation for Zontivity has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.